期刊文献+

肺癌脑转移治疗的新进展 被引量:2

Research progress in treatment of lung cancer with brain metastases
下载PDF
导出
摘要 脑转移瘤是颅内最常见的恶性肿瘤,其原发灶多来源于肺。肺癌患者一旦发生脑转移,预后差,病死率高。自然生存期约1~2个月,如经积极治疗,其中位生存期也仅有4~12个月。目前研究显示,脑转移肺癌患者的预后与影像学技术、放疗技术、手术方式等密切相关。近年来,随着放疗技术的提高、手术方式的改进、以及靶向药物的不断开发利用,患者的生存时间有了很大延长,生活质量也有了明显提高。本文从肺癌脑转移的放疗、化疗、手术治疗及小分子靶向治疗4个方面系统阐释肺癌脑转移治疗的研究进展。 Metastatic encephaloma is the most common malignant tumor in the brain,and most primary tumors originate in the lungs.Brain metastasis of lung cancer results in poor prognosis and high mortality rate,with a natural survival of about 1-2 months and median survival of only 4-12 months even after active treatment.Current studies have shown that the prognosis of lung cancer patients with brain metastasis is closely related to imaging technology,radiotherapy technology,and surgical modality.With the improvement of radiotherapy technology and surgical methods,and the continuous development and utilization of targeted drugs in recent years,the survival of the patients has been largely prolonged,and the life quality has been significantly improved.This paper reviews systematically the research progress in brain metastasis of lung cancer in the aspects of radiotherapy,chemotherapy,surgical treatment and small molecule targeted treatment.
作者 王又君 张兴旭 郭静 周鑫 赵如涵 王田田 吕喜英 WANG You-Jun;ZHANG Xing-Xu;GUO Jing;ZHOU Xin;ZHAO Ru-Han;WANG Tian-Tian;LYU Xi-Ying(Graduate School,Affiliated Hospital,Chengde Medical College,Chengde 067000,China;Department of Oncology,Affiliated Hospital,Chengde Medical College,Chengde 067000,China)
出处 《中华老年多器官疾病杂志》 2020年第6期477-480,共4页 Chinese Journal of Multiple Organ Diseases in the Elderly
关键词 肺癌 脑转移 治疗技术 lung cancer brain metastasis treatnent
  • 相关文献

参考文献4

二级参考文献35

  • 1Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量:345
  • 2刘晓晴,汤传昊,高红军,李俭杰,王维威.靶向药物吉非替尼单药治疗晚期非小细胞肺癌[J].军事医学科学院院刊,2006,30(5):447-449. 被引量:8
  • 3陈明立,谭远发.我国东中西部三大区域人口竞争力实证比较研究[J].经济学家,2007(2):53-63. 被引量:6
  • 4[1]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-celllung cancer(The IDEAL I Trial).J Clin Oncol,2003,21:2237-2246.
  • 5[2]Douillard JY,Giaccone G,Horai T,et al Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lunng cancer (NSCLC) treated with ZDl839 (Iressa)(IDEAL 1).Proc Am Soc Clin Oncol,2002,21:1195.
  • 6[3]Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small-cell lung cancer:a randomized trial.JAMA,2003,290:2149-2158.
  • 7[4]Natale RB,Skarin AT,Maddox AM,et al.Improvement in symptoms and quality of life for advanced nonsmall-cell lung cancer patients receiving ZDl839 (IDEAL 2).Proc Am Soc Clin Oncol,2002,21:1167.
  • 8[5]The Elderly Lung Cancer Vinorelbine Italian Study Group.Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer.J Natl Cancer Inst,1999,91:66-72.
  • 9[6]Gridelh C,Cigolan S,Gallo C,et al.MIL ES investigators.Activity and toxicity of gemcitabine and gemcitabine +vinorelbine in advanced non small cell lung cancer elderly patients:a phaseⅡ data from multicenter Italian lung cancer in the elderly study (MILES)randomized trial.Lung Cancer,2001,31:277-284.
  • 10[7]Quoix E,Breton JL,Ducolone A,et al.First linechemotherapy with gemcitabine in advanced non small cell lung cancer elderly patients:a randomized phaseⅡ study of 3-week versus 4-week schedule.Lung Cancer,2005,47:405-412.

共引文献1216

同被引文献21

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部